Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

Study acronym: GAP
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv19
  2. Site contact updatedv18
  3. Site contact updatedv17
  4. Primary and study completion dates: Jul 2025 to Jul 2030
    • Site contact updated
    v16
  5. Study site revisedv15
Show 13 earlier versionsHide 13 earlier versions
  1. 2 versions Re-verified since Sep 15, 2020, no change to tracked fieldsv13-v14
  2. Primary and study completion dates: Jul 2020 to Jul 2025v12
  3. 2 versions Re-verified since Jul 24, 2017, no change to tracked fieldsv10-v11
  4. Site contact updatedv9
  5. Enrollment target: 150 to 500
    • Primary and study completion dates: Jul 2015 to Jul 2020
    • Site contact updated
    v8
  6. Re-verified, no change to tracked fieldsv7
  7. Primary completion date: Jul 2015v6 Show 4 more changesShow less
    • Study completion date: Jul 2010 to Jul 2015
    • Site contact updated
    • Eligibility criteria expanded, about 2 words
    • Study description shortened, about 5 words
  8. Re-verified, no change to tracked fieldsv5
  9. Eligibility criteria expanded, about 6 words
    • Study title expanded, about 3 words
    v4
  10. Study completion date: Apr 2007 to Jul 2010
    • Site details revised
    • Eligibility criteria expanded, about 3 words
    v3
  11. Study completion date: Apr 2007
    • Site contact updated
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Trial Details
NCT Number NCT00373841
Lead Sponsor University of Pittsburgh
Conditions
(from sponsor)		 Idiopathic Pulmonary Fibrosis
Related terms Fibrosis, Idiopathic Pulmonary Fibrosis
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov